Krebs Biochemicals & Industries Ltd (KREBSBIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 142337,
    "name": "Krebs Biochem",
    "stock_name": "Krebs Biochem",
    "full_name": "Krebs Biochemicals & Industries Ltd",
    "name_url": "stocks-analysis/krebs-biochem",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "74.11",
    "chg": 10.17,
    "chgp": "15.91%",
    "dir": 1,
    "prev_price": "63.94",
    "mcapval": "159.79 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524518,
    "symbol": "KREBSBIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE268B01013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "9.69 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/krebs-biochem-142337-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Krebs Biochem falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-krebs-biochem-fallingrising-3693428",
        "imagepath": "",
        "date": "2025-11-12 22:09:28",
        "description": "As of 12-Nov, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at Rs 66.89, which reflects a decrease of Rs 3.05 or 4.36%. The stock has underperformed significantly today, with a performance that is 5.34% lower than its sector. It opened with a loss of 2.77% and reached an intraday low of Rs 66.89. Additionally, the stock is trading below all key moving averages, indicating a bearish trend. Over the past week, the stock has fallen by 5.51%, and its year-to-date performance shows a substantial decline of 27.69%. Notably, investor participation has dropped sharply, with delivery volume plummeting by 92.31% compared to the five-day average, suggesting a lack of confidence among investors.\n\nIn the broader market context, Krebs Biochem's performance contrasts sharply with the Sensex, which has gained 1.21% over the past week and 8.10% year-to-date. This divergence indi..."
      },
      {
        "title": "Krebs Biochemicals Declines 1.53% Amid Notable Buying Trend Despite Year-to-Date Drop of 28.81%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/krebs-biochemicals-declines-153-amid-notable-buying-trend-despite-year-to-date-drop-of-2881-3688860",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KrebsBiochemica_only_buyers_3688860.png",
        "date": "2025-11-11 09:45:15",
        "description": "Krebs Biochemicals & Industries Ltd is experiencing notable buying activity amid a downward trend in its stock performance. Despite recent declines and significant long-term challenges, market participants appear to be exploring opportunities in this microcap stock within the pharmaceuticals and biotechnology sector."
      },
      {
        "title": "How has been the historical performance of Krebs Biochem?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-krebs-biochem-3672078",
        "imagepath": "",
        "date": "2025-11-04 22:51:08",
        "description": "Answer:\nThe historical performance of Krebs Biochem shows a trend of declining net sales and increasing losses over the years.\n\nBreakdown:\nKrebs Biochem's net sales decreased from 52.94 Cr in Mar'22 to 43.31 Cr in Mar'25, reflecting a downward trend. Other operating income, which was 6.76 Cr in Mar'22, has dropped to zero by Mar'25, contributing to a total operating income decline from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25. The total expenditure, excluding depreciation, has also decreased from 93.69 Cr in Mar'22 to 58.34 Cr in Mar'25. However, the operating profit (PBDIT) remains negative, worsening from -33.99 Cr in Mar'22 to -14.32 Cr in Mar'25. The profit before tax and profit after tax have shown similar negative trends, with losses increasing from -44.53 Cr and -44.53 Cr in Mar'22 to -26.92 Cr and -26.94 Cr in Mar'25, respectively. The company's total liabilities have increased from 159.22 Cr in Mar..."
      },
      {
        "title": "Are Krebs Biochem latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-krebs-biochem-latest-results-good-or-bad-3671648",
        "imagepath": "",
        "date": "2025-11-04 19:45:52",
        "description": "Krebs Biochemicals' latest financial results for Q2 FY26 indicate a challenging operational environment characterized by significant revenue decline and persistent losses. The company reported net sales of ₹4.17 crores, reflecting a year-on-year decrease of 67.57% from ₹12.86 crores in the same quarter last year. This decline in revenue is compounded by a sequential contraction of 23.91% from ₹5.48 crores in Q1 FY26, highlighting a troubling trend of diminishing sales.\n\nThe operational performance further deteriorated, with an operating margin of -66.91%, indicating that the company is losing a substantial portion of its revenue at the operational level. The net loss for the quarter stood at ₹6.14 crores, which represents a 15.41% increase in losses compared to the previous quarter. This ongoing financial distress is underscored by a negative book value of ₹-67.83 per share, demonstrating that the company's..."
      },
      {
        "title": "Krebs Biochemicals Q2 FY26: Deepening Losses Signal Existential Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/krebs-biochemicals-q2-fy26-deepening-losses-signal-existential-crisis-3671273",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KrebsBiochemica_quaterlyResult_3671273.png",
        "date": "2025-11-04 16:31:21",
        "description": "Krebs Biochemicals & Industries Ltd., a niche pharmaceutical manufacturer specialising in Active Pharmaceutical Ingredients (APIs) through fermentation processes, reported a catastrophic Q2 FY26 performance that underscores the company's worsening financial distress. Net losses widened to ₹6.14 crores in Q2 FY26 from ₹5.32 crores in Q1 FY26, marking a 15.41% sequential deterioration. On a year-on-year basis, losses expanded by 6.60% from ₹5.76 crores in Q2 FY25. The micro-cap company, with a market capitalisation of just ₹155.00 crores, saw its stock trade at ₹70.79 on November 4, reflecting persistent investor concerns about viability."
      },
      {
        "title": "Krebs Biochemicals Faces Significant Selling Pressure with Year-to-Date Loss of 23.66%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/krebs-biochemicals-faces-significant-selling-pressure-with-year-to-date-loss-of-2366-3655618",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/KrebsBiochemica_only_sellers_3655618.png",
        "date": "2025-10-29 11:15:12",
        "description": "Krebs Biochemicals & Industries Ltd is experiencing notable selling pressure, continuing a trend of losses. The stock has underperformed compared to the Sensex over various periods, with significant declines year-to-date. Erratic trading patterns and moving averages indicate a challenging market environment for the microcap pharmaceutical company."
      },
      {
        "title": "Why is Krebs Biochem falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-krebs-biochem-fallingrising-3615804",
        "imagepath": "",
        "date": "2025-10-13 21:49:26",
        "description": "As of 13-Oct, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at Rs 70.55, which reflects a decrease of Rs 1.6 or 2.22%. Today's price summary indicates that the stock opened with a gain of 4.93% but subsequently fell to an intraday low of Rs 70.55. The stock has shown high volatility today, with an intraday volatility of 5.74%, and it is trading below all its moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 81.42% compared to the 5-day average, suggesting a lack of confidence among investors.\n\nIn the broader market context, Krebs Biochem's performance over the past week has underperformed the Sensex, with a return of -0.63% compared to the benchmark's +0.66%. Over the past month, the stock has declined by 8.68%, while the Sensex has increased by 0.52%. Year-to-date, Krebs Biochem is down 2..."
      },
      {
        "title": "Why is Krebs Biochem falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-krebs-biochem-fallingrising-3604791",
        "imagepath": "",
        "date": "2025-10-08 22:07:52",
        "description": "As of 08-Oct, Krebs Biochemicals & Industries Ltd is experiencing a price increase, currently at Rs 75.93, reflecting a rise of Rs 3.73 or 5.17%. The stock has shown positive performance today, outperforming its sector by 5.83% and has gained consecutively over the last two days, accumulating a total return of 6.94% during this period. However, despite this recent uptick, the stock has a year-to-date decline of 17.91% and has been highly volatile, with an intraday volatility of 7.46%. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 31.79% against the 5-day average, indicating a potential concern regarding sustained interest in the stock.\n\nIn the broader market context, Krebs Biochem's short-term performance over the past week shows a return of 3.10%, which is significantly higher than the Sensex's return of 0.98% during the same period. This suggest..."
      },
      {
        "title": "Why is Krebs Biochem falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-krebs-biochem-fallingrising-3575101",
        "imagepath": "",
        "date": "2025-09-26 21:44:40",
        "description": "As of 26-Sep, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at Rs 70.50, reflecting a decrease of 3.64 points or 4.91%. The stock has underperformed its sector by 2.57% today and has been on a downward trend for the last three days, accumulating a total loss of 12.96% during this period. Key financial indicators reveal that the company has reported negative results for the last three consecutive quarters, with net sales and profit after tax both declining by 53.42%. Additionally, the company has a negative book value and a weak long-term fundamental strength, as evidenced by a debt-to-equity ratio of zero and poor growth rates in net sales and operating profit over the past five years. \n\nIn the broader market context, Krebs Biochem's performance has been notably weaker than the benchmark, with a year-to-date return of -23.78% compared to the Sensex's gain of 2.9..."
      }
    ],
    "total": 111,
    "sid": "142337",
    "stock_news_url": "https://www.marketsmojo.com/news/krebs-biochemicals-industries-142337"
  },
  "announcements": [
    {
      "caption": "Report On Re-Lodgement Of Transfer Requests Of Physical Shares Nov 2025",
      "datetime": "03-Dec-2025",
      "details": "The Company enclosing herewith RTA report on relodgement of trasnfer request of physical shares for the month Nov 2025.",
      "source": "BSE"
    },
    {
      "caption": "Report On Re-Lodgement Of Transfer Requests Of Physical Shares Oct 2025",
      "datetime": "18-Nov-2025",
      "details": "The Company has enclosed herewith re-lodgement certificate received from RTA.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "05-Nov-2025",
      "details": "The Company has enclosed herewith copy of newspapers advertisement for financial results for the quarter and half year ended 30.09.2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Krebs Biochemicals & Industries Ltd has announced <strong>21:100</strong> rights issue, ex-date: 31 Jan 19",
          "dt": "2019-01-31",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Why is Krebs Biochem falling/rising?

2025-11-12 22:09:28

As of 12-Nov, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at Rs 66.89, which reflects a decrease of Rs 3.05 or 4.36%. The stock has underperformed significantly today, with a performance that is 5.34% lower than its sector. It opened with a loss of 2.77% and reached an intraday low of Rs 66.89. Additionally, the stock is trading below all key moving averages, indicating a bearish trend. Over the past week, the stock has fallen by 5.51%, and its year-to-date performance shows a substantial decline of 27.69%. Notably, investor participation has dropped sharply, with delivery volume plummeting by 92.31% compared to the five-day average, suggesting a lack of confidence among investors. In the broader market context, Krebs Biochem's performance contrasts sharply with the Sensex, which has gained 1.21% over the past week and 8.10% year-to-date. This divergence indi...

Krebs Biochemicals Declines 1.53% Amid Notable Buying Trend Despite Year-to-Date Drop of 28.81%

2025-11-11 09:45:15

Krebs Biochemicals & Industries Ltd is experiencing notable buying activity amid a downward trend in its stock performance. Despite recent declines and significant long-term challenges, market participants appear to be exploring opportunities in this microcap stock within the pharmaceuticals and biotechnology sector.

How has been the historical performance of Krebs Biochem?

2025-11-04 22:51:08

Answer: The historical performance of Krebs Biochem shows a trend of declining net sales and increasing losses over the years. Breakdown: Krebs Biochem's net sales decreased from 52.94 Cr in Mar'22 to 43.31 Cr in Mar'25, reflecting a downward trend. Other operating income, which was 6.76 Cr in Mar'22, has dropped to zero by Mar'25, contributing to a total operating income decline from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25. The total expenditure, excluding depreciation, has also decreased from 93.69 Cr in Mar'22 to 58.34 Cr in Mar'25. However, the operating profit (PBDIT) remains negative, worsening from -33.99 Cr in Mar'22 to -14.32 Cr in Mar'25. The profit before tax and profit after tax have shown similar negative trends, with losses increasing from -44.53 Cr and -44.53 Cr in Mar'22 to -26.92 Cr and -26.94 Cr in Mar'25, respectively. The company's total liabilities have increased from 159.22 Cr in Mar...

Are Krebs Biochem latest results good or bad?

2025-11-04 19:45:52

Krebs Biochemicals' latest financial results for Q2 FY26 indicate a challenging operational environment characterized by significant revenue decline and persistent losses. The company reported net sales of ₹4.17 crores, reflecting a year-on-year decrease of 67.57% from ₹12.86 crores in the same quarter last year. This decline in revenue is compounded by a sequential contraction of 23.91% from ₹5.48 crores in Q1 FY26, highlighting a troubling trend of diminishing sales. The operational performance further deteriorated, with an operating margin of -66.91%, indicating that the company is losing a substantial portion of its revenue at the operational level. The net loss for the quarter stood at ₹6.14 crores, which represents a 15.41% increase in losses compared to the previous quarter. This ongoing financial distress is underscored by a negative book value of ₹-67.83 per share, demonstrating that the company's...

Krebs Biochemicals Q2 FY26: Deepening Losses Signal Existential Crisis

2025-11-04 16:31:21

Krebs Biochemicals & Industries Ltd., a niche pharmaceutical manufacturer specialising in Active Pharmaceutical Ingredients (APIs) through fermentation processes, reported a catastrophic Q2 FY26 performance that underscores the company's worsening financial distress. Net losses widened to ₹6.14 crores in Q2 FY26 from ₹5.32 crores in Q1 FY26, marking a 15.41% sequential deterioration. On a year-on-year basis, losses expanded by 6.60% from ₹5.76 crores in Q2 FY25. The micro-cap company, with a market capitalisation of just ₹155.00 crores, saw its stock trade at ₹70.79 on November 4, reflecting persistent investor concerns about viability.

Krebs Biochemicals Faces Significant Selling Pressure with Year-to-Date Loss of 23.66%

2025-10-29 11:15:12

Krebs Biochemicals & Industries Ltd is experiencing notable selling pressure, continuing a trend of losses. The stock has underperformed compared to the Sensex over various periods, with significant declines year-to-date. Erratic trading patterns and moving averages indicate a challenging market environment for the microcap pharmaceutical company.

Why is Krebs Biochem falling/rising?

2025-10-13 21:49:26

As of 13-Oct, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at Rs 70.55, which reflects a decrease of Rs 1.6 or 2.22%. Today's price summary indicates that the stock opened with a gain of 4.93% but subsequently fell to an intraday low of Rs 70.55. The stock has shown high volatility today, with an intraday volatility of 5.74%, and it is trading below all its moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 81.42% compared to the 5-day average, suggesting a lack of confidence among investors. In the broader market context, Krebs Biochem's performance over the past week has underperformed the Sensex, with a return of -0.63% compared to the benchmark's +0.66%. Over the past month, the stock has declined by 8.68%, while the Sensex has increased by 0.52%. Year-to-date, Krebs Biochem is down 2...

Why is Krebs Biochem falling/rising?

2025-10-08 22:07:52

As of 08-Oct, Krebs Biochemicals & Industries Ltd is experiencing a price increase, currently at Rs 75.93, reflecting a rise of Rs 3.73 or 5.17%. The stock has shown positive performance today, outperforming its sector by 5.83% and has gained consecutively over the last two days, accumulating a total return of 6.94% during this period. However, despite this recent uptick, the stock has a year-to-date decline of 17.91% and has been highly volatile, with an intraday volatility of 7.46%. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 31.79% against the 5-day average, indicating a potential concern regarding sustained interest in the stock. In the broader market context, Krebs Biochem's short-term performance over the past week shows a return of 3.10%, which is significantly higher than the Sensex's return of 0.98% during the same period. This suggest...

Why is Krebs Biochem falling/rising?

2025-09-26 21:44:40

As of 26-Sep, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at Rs 70.50, reflecting a decrease of 3.64 points or 4.91%. The stock has underperformed its sector by 2.57% today and has been on a downward trend for the last three days, accumulating a total loss of 12.96% during this period. Key financial indicators reveal that the company has reported negative results for the last three consecutive quarters, with net sales and profit after tax both declining by 53.42%. Additionally, the company has a negative book value and a weak long-term fundamental strength, as evidenced by a debt-to-equity ratio of zero and poor growth rates in net sales and operating profit over the past five years. In the broader market context, Krebs Biochem's performance has been notably weaker than the benchmark, with a year-to-date return of -23.78% compared to the Sensex's gain of 2.9...

View All News